Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics Laura TadvalkarSeptember 30, 2019
Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform Laura TadvalkarSeptember 27, 2019
Sonde Completes $16 Million Series A Financing Round to Advance Vocal Biomarker Technology. Brennan CaruthersApril 11, 2019
QurAlis Raises $5.5 million Seed Round -- Wins Pfizer Sponsored Golden Ticket to LabCentral -- -- Becomes Resident of JLABS @ LabCentral -- Brennan CaruthersNovember 19, 2018
Ribometrix Announces $30 Million Series A Funding to Advance Pipeline of RNA-Targeting Small Molecule Therapies. Brennan CaruthersNovember 13, 2018
F‐star Announces Early Exercise by Denali Therapeutics of its Option to Acquire F‐star Gamma. Brennan CaruthersMay 30, 2018
QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, United in the Fight to Cure ALS. Brennan CaruthersApril 5, 2018
Ribometrix Raises $7.5M In Seed Funding to Advance Platform for Discovering and Developing Small Molecule Modulators of RNA to Treat Human Diseases. Brennan CaruthersOctober 31, 2017
Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology. Brennan CaruthersSeptember 6, 2017
F-star Expands its Relationship with Merck through a new Strategic Collaboration to Develop Bispecific Antibodies in Immuno-Oncology. Brennan CaruthersJune 4, 2017
Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer. Brennan CaruthersMay 3, 2017
Forge Therapeutics Raises $15M Series A Financing to Develop First Novel Gram-Negative Antibiotic In Decades. Brennan CaruthersApril 25, 2017
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing. Brennan CaruthersFebruary 13, 2017
miRagen Therapeutics Announces Presentation of MRG-106 Clinical Data at American Society of Hematology Annual Meeting. Brennan CaruthersNovember 3, 2016
miRagen Therapeutics Appoints Kevin Koch, Ph.D., to Its Board of Directors. Brennan CaruthersSeptember 9, 2016
F‐star Announces Collaborative Agreement with Denali Therapeutics for the Development of a Multispecific Antibody Platform to Deliver Therapeutics Across the Blood‐Brain Barrier. Brennan CaruthersAugust 25, 2016
